Fetal exome sequencing: yield and limitations in a tertiary referral center
- 2 January 2019
- journal article
- research article
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 53 (1) , 80-86
Abstract
Objective: To explore the indications for and diagnostic outcomes of fetal exome sequencing in a tertiary referral center.Methods: Between 2012 and 2017, 77 unrelated fetal samples from pregnancies referred to our center underwent exome sequencing. The cohort included 37 fetuses, 36 products of conception (from cases of pregnancy termination or intrauterine fetal death), one case with DNA from both the fetus and a previous termination of pregnancy, and three cases with DNA of unknown origin. Exome sequencing was performed on DNA extracted from amniocytes or fetal tissue and, in some cases, from parental peripheral blood. Indications, turnaround time, diagnostic rates and pregnancy outcomes were investigated. Diagnostic yield was analyzed according to consanguinity (yes or no), sample type (proband only, or trio or other) and referral indication (malformation or isolated nuchal translucency (NT)).Results: The most common indication for fetal exome sequencing was multiple malformations (21/77, 27%), followed by isolated brain malformation (15/77, 19%). Twelve (16%) fetuses were referred for isolated increased NT. Exome analysis was diagnostic for 16 fetuses (21%); when subclassified into fetal malformations vs isolated increased NT it became clear that exome analysis did not reveal any known or probable pathogenic variants in cases referred for isolated increased NT, whereas, among the remaining fetuses, a molecular diagnosis was reached in 16/65 (25%). Proband‐only cases received a diagnosis more often than did cases that had trio exome sequencing.Conclusions: Exome sequencing has the potential to provide molecular diagnoses in cases in which conventional prenatal cytogenetic testing is negative. Referral bias of consanguineous cases could account for the high diagnostic rate of proband‐only sequencing. Syndrome‐specific prognostic information enables parents to make informed decisions, whereas challenges include time limitations and variant interpretation in the setting of non‐specific fetal findings. As we report only established disease–gene associations, further segregation and functional studies in a research setting are expected to increase significantly the diagnostic yield. Copyright © 2018 ISUOG. Published by John Wiley & Sons Ltd.Keywords
Funding Information
- Karl Kahane Foundation
This publication has 19 references indexed in Scilit:
- Exome sequencing positively identified relevant alterations in more than half of cases with an indication of prenatal ultrasound anomaliesPrenatal Diagnosis, 2015
- Molecular Findings Among Patients Referred for Clinical Whole-Exome SequencingJAMA, 2014
- Chromosomal Microarray Analysis and Prenatal DiagnosisObstetrical & Gynecological Survey, 2014
- Exome sequence read depth methods for identifying copy number changesBriefings in Bioinformatics, 2014
- Exome sequencing improves genetic diagnosis of structural fetal abnormalities revealed by ultrasoundHuman Molecular Genetics, 2014
- The clinical utility of microarray technologies applied to prenatal cytogenetics in the presence of a normal conventional karyotype: a review of the literaturePrenatal Diagnosis, 2013
- Detection of Clinically Relevant Copy Number Variants with Whole-Exome SequencingHuman Mutation, 2013
- Chromosomal Microarray versus Karyotyping for Prenatal DiagnosisNew England Journal of Medicine, 2012
- Increased nuchal translucency in euploid fetuses—what should we be telling the parents?Prenatal Diagnosis, 2010
- Increased nuchal translucency thickness and normal karyotype: time for parental reassuranceUltrasound in Obstetrics & Gynecology, 2007